At the recent World Conference on Lung Cancer (WCLC), the results of the phase III HARMONI 2 trial were reported, showing that first-line ivonescimab compared to pembrolizumab had led to significantly longer median PFS (11.14 m vs. 5.82 m; HR 0.51; 95% CI 0.38–0.69; p < 0.0001) in advanced NSCLC patients with a positive PD-L1 score. This evidence concerns the gene CD274 and non-small cell lung carcinoma.